# Chris De Jonghe

> Chris De Jonghe is a Series A investor at Vinnof (Netherlands) backing Biotechnology and Medical. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Vinnof](https://shizune.co/investors/profile/vinnof)
- Location: Netherlands, United States
- Total investments: 3
- Last investment: Apr 2024
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: http://be.linkedin.com/pub/chris-de-jonghe/9/3a9/72

Chris De Jonghe is a Series A investor at Vinnof in Netherlands focused on Biotechnology and Medical. Chris De Jonghe - Member, Group Management Committee @ Vinnof

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 67% |
| Medical | 1 | 33% |
| Health Care | 1 | 33% |
| Therapeutics | 1 | 33% |
| Manufacturing | 1 | 33% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 33% |
| Series B | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Belgium | 1 | 33% |
| The Netherlands | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Flindr Therapeutics | Immagene develops personalized cancer immunotherapies to fight multiple cancer type. | $21.4M | Series A | Apr 24, 2024 |  |
| reMYND | Their Contract Research Organization (CRO) helps their clients assess the effects of their experimental Alzheimer treatments in their proprietary mouse models.They serve the majority of the Top 10 pharmaco’s worldwide with clients in the US, Europe and Japan. They have provided pivotal in-vivo proof-of-concept data for several candidate drugscurrently in clinical development, and work actively together with Dr. Sugimoto, the inventor of Aricept. | $14.6M | Series B | Jan 21, 2021 |  |
| reMYND | Their Contract Research Organization (CRO) helps their clients assess the effects of their experimental Alzheimer treatments in their proprietary mouse models.They serve the majority of the Top 10 pharmaco’s worldwide with clients in the US, Europe and Japan. They have provided pivotal in-vivo proof-of-concept data for several candidate drugscurrently in clinical development, and work actively together with Dr. Sugimoto, the inventor of Aricept. | $13.2M | Series B | Dec 18, 2018 |  |

3 of 3 investments shown.

## Co-investors
- [BNP Paribas Fortis](https://shizune.co/investors/profile/bnp-paribas-fortis) — VC Fund, 2 deals together
- [Korys](https://shizune.co/investors/profile/korys) — VC Fund, 2 deals together
- [KU Leuven](https://shizune.co/investors/profile/university-of-leuven) — VC Fund, 2 deals together
- [BOM](https://shizune.co/investors/profile/brabantse-ontwikkelings-maatschappij-bom) — VC Fund, 1 deal together
- [Curie Capital](https://shizune.co/investors/profile/curie-capital) — VC Fund, 1 deal together
- [Flanders Future Techfund](https://shizune.co/investors/profile/flanders-future-techfund) — VC Fund, 1 deal together

## About Vinnof

VC Fund · Brussels, Belgium

Vinnof is a venture capital firm that offers seed capital to innovative, early-stage startups based in Flanders, Belgium.

5 contacts available at Vinnof.

| Name | Title | Profile |
| --- | --- | --- |
| Chris De Jonghe | Member, Group Management Committee | https://shizune.co/investors/profile/chris-de-jonghe |
| Marcel Van Hoven Hand | Chairman | https://shizune.co/investors/profile/marcel-van-hoven-hand |
| Christine Claus | Director | https://shizune.co/investors/profile/christine-claus |
| Clair Ysebaert | Director | https://shizune.co/investors/profile/clair-ysebaert |
| Greta D'Hondt | Director | https://shizune.co/investors/profile/greta-dhondt |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Chris De Jonghe invest in?

Chris De Jonghe invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Chris De Jonghe last invest?

The most recent investment recorded for Chris De Jonghe closed in Apr 2024. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co